Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Operating Leases (2020 - 2025)

IGC Pharma (IGC) has disclosed Operating Leases for 6 consecutive years, with $5000.0 as the latest value for Q3 2025.

  • Quarterly Operating Leases fell 85.71% to $5000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $5000.0 through Sep 2025, down 85.71% year-over-year, with the annual reading at $10000.0 for FY2025, 95.19% down from the prior year.
  • Operating Leases for Q3 2025 was $5000.0 at IGC Pharma, down from $7000.0 in the prior quarter.
  • The five-year high for Operating Leases was $433000.0 in Q2 2021, with the low at $5000.0 in Q3 2025.
  • Average Operating Leases over 5 years is $198631.6, with a median of $207000.0 recorded in 2023.
  • The sharpest move saw Operating Leases rose 0.48% in 2024, then tumbled 95.19% in 2025.
  • Over 5 years, Operating Leases stood at $374000.0 in 2021, then plummeted by 35.56% to $241000.0 in 2022, then crashed by 52.28% to $115000.0 in 2023, then tumbled by 89.57% to $12000.0 in 2024, then plummeted by 58.33% to $5000.0 in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $5000.0, $7000.0, and $10000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.